This isn’t what most people would call a ‘negotiation.’ This is a partisan bill that threatens the future development of new treatments and patient access to life-saving medicines while doing little to fix the broader affordability challenges people are facing,” said Brian Newell, a spokesman for the Pharmaceutical Research and Manufacturers of America, a major industry group and lobbying force.
Washington takes on Big Pharma: Lower drug prices vs. fewer new cures
→
“Threatening hundreds of thousands of jobs, jeopardizing access to medicines and upending an innovative biopharmaceutical industry to pay for unrelated government programs is the wrong approach,” said Brian Newell, spokesman for Pharmaceutical Research and Manufacturers of America, or PhRMA.
House Democrats move toward drug-pricing plan in infrastructure bill
→
